BWH Logo LABORATORY FOR NANOMEDICINE
Sengupta Laboratory
HST Logo
Page Banner Image of a Globe
Harvard University

   Indo-US Joint
   Center for
   Nanobio-
   technology


MIT
    Home     |     Team     |     Publications     |     News     |     Funding
REPRESENTATIVE PUBLICATIONS

  • Sengupta S, Kulkarni A. Design principles for clinical efficacy of cancer nanomedicine: a look into the basics. ACS Nano (2013) 7(4):2878-82.

  • Sarangi S, Pandey A, Papa AL, Sengupta P, Kopparam J, Dadwal U, Basu S, Sengupta S. P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer. Med Oncol. (2013) 30(2):567.

  • Papa AL, Basu S, Sengupta P, Banerjee D, Sengupta S, Harfouche R. Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. BMC Cancer (2012) 12:419.

  • Sengupta P, Basu S, Soni S, Pandey A, Roy B, Oh MS, Chin KT, Paraskar AS, Sarangi S, Connor Y, Sabbisetti VS, Kopparam J, Kulkarni A, Muto K, Amarasiriwardena C, Jayawardene I, Lupoli N, Dinulescu DM, Bonventre JV, Mashelkar RA, Sengupta S. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc. Natl. Acad. Sci. USA (2012) 109:11294-9.

  • Piecewicz SM, Pandey A, Roy B, Xiang SH, Zetter BR, Sengupta S. Insulin-like growth factors promote vasculogenesis in embryonic stem cells. PLoS One (2012) 7(2):e32191.

  • Paraskar A, Soni S, Roy B, Papa AL, Sengupta S. Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology (2012) 23(7):075103.

  • Paraskar A, Soni S, Basu S, Amarasiriwardena CJ, Lupoli N, Srivats S, Roy RS, Sengupta S. Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. Nanotechnology (2011) 22(26):265101.

  • Banerjee D, Harfouche R, Sengupta S. Nanotechnology-mediated targeting of tumor angiogenesis. Vasc. Cell (2011) 3(1):3.

  • Sengupta P, Basu S, Sengupta S. Cancer, signal transduction and nanotechnology. Curr. Drug. Deliv. (2011) 8(3):254-60.

  • Piecewicz S, Sengupta S. The dynamic glycome microenvironment and stem cell differentiation into vasculature. Stem Cells Dev. (2011) 20(5):749-58.

  • Sinha Roy R, Soni S, Harfouche R, Vasudevan PR, Holmes O, de Jonge H, Rowe A, Paraskar A, Hentschel DM, Chirgadze D, Blundell TL, Gherardi E, Mashelkar RA, Sengupta S. Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis. Proc. Natl. Acad. Sci. USA (2010) 107(31):13608-13.

  • Paraskar AS, Soni S, Chin KT, Chaudhuri P, Muto KW, Berkowitz J, Handlogten MW, Alves NJ, Bilgicer B, Dinulescu DM, Mashelkar RA, Sengupta S. Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc. Natl. Acad. Sci. USA (2010) 107(28):12435-40.
    [Featured in Harvard Gazette and MIT News.]

  • Agarwal S, Dugar D, Sengupta S. Ranking chemical structures for drug discovery: a new machine learning approach. J. Chem. Inf. Model. (2010) 50(5):716-31.
    [Featured as an MIT spotlight and news article.]

  • Chaudhuri P, Harfouche R, Soni S, Hentschel DM, Sengupta S. Shape effect of carbon nanovectors on angiogenesis. ACS Nano (2010) 4(1):574-82.

  • Chaudhuri P, Soni S, Sengupta S. Single-walled carbon nanotube-conjugated chemotherapy exhibits increased therapeutic index in melanoma. Nanotechnology (2010) 21(2):025102.

  • Harfouche R, Hentschel D, Piecewicz SM, Basu S, Print C, Eavarone D, Kiziltepe T, Sasisekharan R, Sengupta S. Glycome and transcriptomal regulation of vasculogenesis. Circulation (2009) 120(19):1883-92.

  • Basu S, Chaudhuri P, Sengupta S. Targeting oncogenic signaling pathways by exploiting nanotechnology. Cell Cycle (2009) 8(21):3480-7.

  • Harfouche R, Basu S, Soni S, Hentschel DM, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis (2009) [Epub ahead of print]

  • Chaudhuri P, Paraskar A, Soni S, Mashelkar RA, Sengupta S. Fullerenol-Cytotoxic Conjugates for Cancer Chemotherapy. ACS Nano (2009) 3(9):2505-14.

  • Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc. Natl. Acad. Sci. USA (2009) 106(19):7957-61.
    [Featured in HarvardScience, USNews, The Telegraph, etc.]

  • Sorathyia A, Jucikas T, Piecewicz S, Sengupta S, Lio P. Searching for glycomics role in stem cell development. In Proc. 5th Intl. Meeting on Computational Intelligence Methods for Bioinformatics and Biostatistics (2008).

  • Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer. Br. J. Cancer (2007) 96(9):1315-9.

  • Sengupta S, Eavarone DA, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R. Novel cancer therapy through temporal targeting of both tumor cells and neovasculature using a unique nanoscale delivery system. Nature (2005) 436:568-72.
    [Featured in Nature News and Views, Tech Review, MIT website Spot Light, BBC, MSNBC, FOX TV, The Telegraph, Boston Globe, etc.]

  • Sengupta S, Toh SA, Sellers LA, Skepper JN, Koolwijk P, Leung HW, Yeung HW, Wong RNS, Sasisekharan R, Fan TP. Modulating angiogenesis - The yin and the yang in ginseng. Circulation (2004) 104:1219-1225.
    [Featured in Science Editor's Choice (10th Sep), Forbes (7th Sep), Washington Post (30th Aug), US Today, Petra (5th Sep, Greece), Folca (Brazil), Tech Review (Jan 05), U.S. Department of State release (31st Aug), NIGMS press release.]

  • Qi Y, Zhao G, Liu D, Shriver Z, Sundaram M, Sengupta S, Venkataraman G, Langer R, Sasisekharan R. Delivery of therapeutic levels of heparin and low molecular weight heparin through a pulmonary route. Proc. Natl. Acad. Sci. USA (2004) 101:9867-9872.

  • Sengupta S, Kiziltepe T, Sasisekharan R. A dual color fluorescence imaging-based system for the dissection of the antiangiogenic and chemotherapeutic properties of molecules. FASEB J. (2004) (doi:10.1096/fj.04-1934fje)

  • Johnson NA, Sengupta S, Saidi SA, Lessan K, Charnock-Jones SD, Scott L, Stephens R, Freeman TC, Tom BDM, Harris M, Denyer G, Sundaram M, Sasisekharan R, Smith SK, Print CG. Endothelial cells preparing to die by apoptosis initiate a program of transcriptome and glycome regulation. FASEB J. (2004) 18:188-190.

  • Sengupta S, Sellers LA, Cindrova T, Skepper JN, Gherardi E, Sasisekheran R, Fan TP. Cyclooxygenase-2-selective non steroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis. Cancer Res. (2003) 63:8351-8359.

  • Sengupta S, Sellers LA, Li R, Zhao G, Gherardi E, Sasisekharan R, Fan TP. Targeting of mitogen activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation (2003) 107:2955-2961.

  • Sengupta S, Gherardi E, Sellers LA, Sasisekharan R, Fan TP. Hepatocyte growth factor/scatter factor can induce angiogenesis independent of vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. (2003) 23:69-75.

  • Sengupta S, Sellers LA, Matheson HB, Fan TP. Thymidine phosphorylase induces angiogenesis in vitro and in vivo: an evaluation of possible mechanisms. Br. J. Pharmacol. (2003) 139:219-231.


   Brigham and Women's Hospital   |  Room 317, PRB, 65 Landsdowne Street, Cambridge, MA 02139   |  Tel: 617-768-8994

   © 2008 Sengupta Laboratory